![Citeline Podcasts artwork](https://is1-ssl.mzstatic.com/image/thumb/Podcasts113/v4/0f/4f/ef/0f4fef8f-28fc-8de1-8d89-184cfda23e39/mza_5528053617673757912.jpg/100x100bb.jpg)
2022년 빅파마M&A 선두주자는 화이자, 인수합병 또 나올까?
Citeline Podcasts
English - November 13, 2022 23:20 - 3 minutes - 8.51 MB - ★★★★★ - 24 ratingsBusiness News Business News Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Drug Fix: Election Fallout, IRA Impacting Product Development, Updated FDA Expanded Access Policy
Next Episode: レポート要約 - 1] 臨床試験を牽引するアジア太平洋地域
머크가 400억달러 규모의 씨젠 인수에서 손을 떼는 등 빅파마들이 여전히 인수합병에 나서는 것을 자제하고 있다는 Scrip 기사를 요약한 내용입니다.
https://scrip.pharmaintelligence.informa.com/SC147191/Pfizer-Leads-Big-Pharma-MA-In-2022--But-Is-There-More-To-Come